ストックスクリーナーアプリを入手
8.47
5.04%
-0.45
前日終値:
$8.92
開ける：
$8.81
24時間の取引高:
389.48K
Relative Volume:
0.70
時価総額：
$516.91M
収益：
-
当期純損益:
$-117.81M
株価収益率:
-4.5053
EPS:
-1.88
ネットキャッシュフロー:
$74.30M
1週間 パフォーマンス:
-6.92%
1か月 パフォーマンス:
-0.59%
6か月 パフォーマンス:
+116.07%
1年 パフォーマンス:
+145.51%
1日の値動き範囲:
$8.41
$8.95
1週間の範囲:
$8.31
$9.32
52週間の値動き範囲:
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
名前
Omeros Corporation
セクター
電話
206-676-5000
住所
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
8.47 | 516.91M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2022-12-08 | ダウングレード | UBS | Buy → Neutral |
| 2022-11-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-06-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-10-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2021-10-01 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-09-27 | 開始されました | JP Morgan | Neutral |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-08-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2019-05-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-03-05 | ダウングレード | Needham | Buy → Hold |
| 2017-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2017-05-11 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 繰り返されました | Maxim Group | Buy |
| 2017-03-17 | 繰り返されました | Needham | Buy |
| 2016-11-16 | 繰り返されました | Wedbush | Outperform |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-06-03 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-03-02 | 繰り返されました | Needham | Buy |
| 2016-02-29 | 繰り返されました | Wedbush | Outperform |
| 2015-11-11 | 繰り返されました | Needham | Buy |
| 2015-08-18 | 繰り返されました | WBB Securities | Strong Buy |
| 2015-08-10 | 開始されました | ROTH Capital | Buy |
すべてを表示
Omeros Corporation (OMER) 最新ニュース
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - The Dwinnex
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - Stock Traders Daily
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Omeros Earnings Preview: Key Metrics to Watch in Q4 and Full Year Report - StockTitan
Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Bank of New York Mellon Corp Sells 4,919 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros to activate site for Phase III programme of zaltenibart for PNH - Yahoo Finance
D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros (OMER) Expected to Announce Earnings on Monday - Defense World
Omeros advances Phase 3 trials for PNH treatment zaltenibart - Investing.com
Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart -March 21, 2025 at 12:53 pm EDT - Marketscreener.com
Omeros advances Phase 3 trials for PNH treatment zaltenibart By Investing.com - Investing.com South Africa
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - Joplin Globe
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
US Bancorp DE Takes $81,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
(OMER) On The My Stocks Page - Stock Traders Daily
Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company'S Oms527 Program To Treat Cocaine Use Disorder - Marketscreener.com
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder - Yahoo Finance
Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com - Defense World
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com - Defense World
New York State Common Retirement Fund Increases Stake in Omeros Co. (NASDAQ:OMER) - Defense World
The time has not yet come to remove your chips from the table: Omeros Corporation (OMER) - SETE News
Investor Network: Omeros Corporation to Host Earnings Call - ACCESS Newswire
Blue Trust Inc. Sells 1,910 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven In The Medium-Term - Simply Wall St
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us (OMER) - Seeking Alpha
Trading (OMER) With Integrated Risk Controls - Stock Traders Daily
Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expande - Defense World
Omeros announces results for narsoplimab expanded access program - Yahoo Finance
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA - Business Wire
Can This Drug Cut Death Risk by 66% in Transplant Patients? New Data Reveals Breakthrough - StockTitan
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50 - MarketBeat
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings - Business Wire
Breakthrough TA-TMA Treatment Data: Narsoplimab Shows Promising Results in 128-Patient Study - StockTitan
Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program - BioSpace
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma - Marketscreener.com
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company - Yahoo Finance
SG Americas Securities LLC Has $241,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Navigating OMER Stock: Omeros Corporation Journey - The InvestChronicle
Stordahl Capital Management Inc. Purchases New Shares in Omeros Co. (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Trading Up 5.3%Here's What Happened - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Down 4.4%Here's Why - MarketBeat
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Cantor Fitzgerald Forecasts Omeros FY2025 Earnings - Defense World
Omeros (NASDAQ:OMER) Shares Gap DownTime to Sell? - MarketBeat
Omeros Corporation (OMER) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):